Orthopedic devices are used to treat the disorders and injuries of the musculoskeletal system of human body. Orthobiologics are biomaterials used in orthopedic surgery as an adjunct to faster fusion and healing of the bone. Viscosupplementation is the process by which the synovial fluid at the joints is replaced by a Hyaluronate preparation which has viscous properties similar to the natural synovial fluid. GlobalData uses proprietary data and analytics to provide a comprehensive report on the viscosupplementation devices market, including market shares of different players within Canada. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the viscosupplementation market in Canada was Sanofi followed by Bioventus, Fidia farmaceutici, Anika Therapeutics, Zimmer Biomet and Ferring Pharmaceuticals.
Viscosupplementation is used for the treatment of osteoarthritis of knee and other joints. Other joints include hip, shoulder, ankle, elbow, wrist, hand and foot. Viscosupplementation consists of a treatment cycle of Hyaluronic acid injections which come in variable volumes. One cycle is comprised of 1-injection or 3-injection or 5-injection course. Hyaluronic acid is given as a one-dose injection. Hyaluronic acid is given as a three-dose injection over three weeks. Hyaluronic acid is given as a five-dose injection over five weeks. Bone cement and casting materials are used to fix bone fractures or as a complement to other devices in procedures such as joint reconstruction and trauma fixation.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the viscosupplementation devices market within Canada was expected to be over $30m in 2022.
For the latest complete market share analysis of viscosupplementation device market in Canada, buy the report here.